Related Experiment Videos
Phenotypic evolution of classic 21-hydroxylase deficiency
W H Hoffman1, M Y Shin, P A Donohoue
1Department of Pediatrics, Medical College of Georgia, Augusta 30912-3785, USA.
Clinical Endocrinology
|July 1, 1996
Summary
A patient with salt-losing congenital adrenal hyperplasia (CAH) stopped medication at 17 and remained asymptomatic, despite abnormal hormone levels. This suggests potential alterations in CYP21 gene expression with age or hormonal changes.
Area of Science:
- Endocrinology
- Genetics
- Reproductive Medicine
Background:
- Congenital adrenal hyperplasia (CAH) is a group of genetic disorders affecting the adrenal glands.
- Classic salt-losing CAH requires lifelong mineralocorticoid and glucocorticoid replacement therapy.
- Patient non-adherence to treatment can lead to significant health complications.